Results 211 to 220 of about 103,365 (348)

Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials [PDF]

Alessandro Mantovani, Riccardo Morandin, Veronica Fiorio, Maria Giovanna Lando, Norbert Stefan, Herbert Tilg, Christopher D. Byrne, Giovanni Targher   +7 more
openalex   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. [PDF]

ESC Heart Fail
Ibrahim R, Nhat H, Abdelnabi M, Forst B, Allam M, Mee XC, Lim GK, Bcharah G, Barry T, Farina J, Ayoub C, Arsanjani R, Lee K.   +12 more
europepmc   +1 more source

Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Comment on Br J Anaesth 2024; 132: 644–8 [PDF]

Paul Potnuru, Nadia Hernandez, Omonele O. Nwokolo, Sudipta Sen   +3 more
openalex   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types. [PDF]

Discov Oncol
Alba MM, Lee WH, Lee JSH, Lu Z, Stiles B, Ligumsky H.   +5 more
europepmc   +1 more source

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice

, 2017
Leena Liljedahl, Jenny Norlin, James N. McGuire, Peter James   +3 more
openalex   +1 more source

Biogenesis of Organelles and Membrane Proteins. [PDF]

, 1988
Harmey, Matthew A., Neupert, Walter, Nicholson, Donald W., Stuart, Rosemary A.   +3 more
core   +1 more source

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti, Matt Capehorn, Esther Artime, Lill‐Brith von Arx, Alun L. Davies, Atif Adam, Anastasia Lampropoulou   +6 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. [PDF]

Cancers (Basel)
Ailawadi S, Murphy JE, Storandt MH, Mahipal A.   +3 more
europepmc   +1 more source